Genesis Research Group’s ISPOR Europe award-winning poster authors interviewed online
December 3, 2024 | HTA, Health Technology Assessments, ISPOR Europe, Payers, RWE, ispor, payer insights, real-world evidence
Genesis Research Group’s poster ‘Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey’ was recently named as ‘Best General Poster Research Presentation’ for ISPOR Europe 2024.
Along with other Genesis Research Group presentations, the poster has recently been featured by The Evidence Base in an interview entitled ‘Payer Perspectives on Key Challenges in Healthcare Decision-Making: actionable insights for life sciences companies’.
Prior to being awarded ‘Best General Poster Research Presentation‘ for ISPOR Europe 2024, authors of the poster ‘Payer Perspective on the Impact of Real-world Evidence in Health Technology Assessments of Precision Oncology Treatments Across Europe: Results From an Online Survey‘ were interviewed by The Evidence Base alongside other Genesis Research Group authors.
Payer perspectives are essential in ensuring that new treatments demonstrate not only clinical efficacy but also cost-effectiveness, while aligning with the priorities and sustainability of healthcare systems. For life sciences companies, understanding payer approaches to the complex challenges of reimbursement decision-making—including budget impact assessments, cost-effectiveness analyses, and evaluations of clinical value—is critical for shaping patient access to innovative therapies and informing healthcare policy.
In this interview, The Evidence Base spoke with Tijana Ignjatovic, Darrin Benjumea, and Manica Agrawal about new research that focuses on gathering payer perspectives on these key issues in healthcare. The survey results were recently presented at ISPOR Europe 2024 (November 17–20, 2024, Barcelona, Spain).
Darren Benjumea was the co-author and presenter of the previously mentioned ISPOR Europe winning poster, the additional authors being Tijana Ignjatovic, Alice Jackson, Kristen Downs, and Lynn Okamoto.
Congratulations to the Genesis Research Group team!
You can read the article online or contact Genesis Research Group at solutions@genesisrg.com if you’d like a copy of the poster.
This content was provided by Genesis Research Group
Company Details
Latest Content from Genesis Research Group
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…
MFN Pricing Is Moving Fast – Here’s What Matters
With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…
ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment
In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…
Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview
At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…
Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212
Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation…
Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies
HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.
Genesis Research Group Appoints Tim Wright as Executive Vice President, Access and Pricing
Genesis Research Group, a leading provider of tech-enabled real-world evidence (RWE), health economics and outcomes research (HEOR), and market access services, announces the appointment of Tim Wright as Executive Vice…
Navigating US market access analytics: A conversation with Ki Park
In the rapidly evolving landscape of healthcare and pharmaceutical market access, data analytics has become a critical component for making informed decisions. We sat down with Ki Park, our Vice…
Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group’s recent expansion of its real-world data…